Please login to the form below

Apeiron

This page shows the latest Apeiron news and features for those working in and with pharma, biotech and healthcare.

Keytruda and Opdivo backed for new uses in Europe

Apeiron Biologics also got the go-ahead for Dinutuximab beta as a treatment for high-risk neuroblastoma, an orphan indication.

Latest news

Sanofi and Novartis snap up immuno-oncology candidates

BioNtech - signed last year alongside smaller deals with Selecta, Evotec and Apeiron Biologics.
Sanofi forges $1.5bn cancer partnership with BioNTech

Set to develop five cancer therapies
Sanofi and Evotec to work together on diabetes and cancer

injections. Meanwhile, the two companies have also agreed to work together with Apeiron Biologics on novel, small-molecule immuno-oncology therapies. ... Sanofi will support two years of research funding for Evotec and Apeiron and could potentially yield
Advancing acquisitions

Apeiron Biologics AG/GSK. APN01 - recombinant human angiotensin converting enzyme 2 (rhACE2) in ARDS.
GSK enters licensing deal for ARDS enzyme

Apeiron has granted GSK exclusive rights to its APN01 enzyme, in phase I development to treat Acute Respiratory Distress Syndrome. ... The deal will see GSK pay Apeiron an up-front payment of £11m cash and equity investment.

More from news
Approximately 2 fully matching, plus 4 partially matching documents found.

Latest Intelligence

Pharma deals in August 2015

Immunology deals. In addition to this and in keeping with the industry fashion, Sanofi has ventured into immuno-oncology with Evotec / Apeiron Biologics. ... As a strategic collaboration it is fairly risk sparing and accesses Apeiron's immunological

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

BMS appoints new commercial leader, Davies joins Eisai and more

Apeiron expands board. Cancer Immunotherapy company Apeiron has expanded its board, appointing Anderson Gaweco as its chief medical and scientific officer. ... major near-term milestones of clinical-stage assets and support the expansion and
Apeiron bolsters management board

Peter Llewellyn-Davies joins as its CFO and CBO. Viennese cancer-immunotherapy focused group Apeiron Biologics has appointed a new chief financial officer and chief business officer in the form of ... He said: “Apeiron is currently amongst the most

More from appointments
Approximately 2 fully matching, plus 0 partially matching documents found.

Featured jobs

Account/ Project Director – Medical Affairs – Surrey: Salary TBC

Account Director, Medical Education: Salary TBC

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Senior Medical Writer: Salary TBC

Project/ Events Manager – Medical Education and Events Agency: Salary TBC

Account Director, Healthcare Marketing Agency: Salary TBC

PR Director – Health & Wellbeing – Mat Cover (4 days a week)...: Salary TBC

Editorial Assistant Medical Education Agency: £25, 000 - £26, 000

Senior Planner – Healthcare Advertising – New Role: Salary TBC

Project Manager/ Account Manager: Salary TBC

Digital Account Director: Salary TBC

AD – Corporate Comms/ Public Affairs/ B2B – Healthcare Focus: Salary TBC

Senior Medical Writer: Great salary and benefits

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Senior Medical Writer: Up to £50, 000 with Benefits

Subscribe to our email news alerts

PMHub

Add my company

Virgo Health

Virgo Health is an award-winning global healthcare communications and medical education agency comprising specialists with some of the best skills,...

Latest intelligence

International Childhood Cancer Day 2019: The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues: Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups: A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...